Business Context and Reporting Period
This Form 8-K, dated June 12, 2015, reports on Ruthigen, Inc. (the registrant) and its proposed merger with Pulmatrix, Inc. The filing details the successful approval of the Merger Agreement by Ruthigen stockholders at a special meeting and the simultaneous closing of a private placement offering.
Key Financial Metrics and Capital Events
- Private Placement: Ruthigen accepted subscriptions from 34 accredited investors for 948,464 shares of common stock at $2.75 per share.
- Gross Proceeds: Approximately $2.6 million.
- Condition Precedent: The closing of the private placement is conditioned upon the closing of the Merger.
- Merger Consideration: Includes issuance of Ruthigen common stock to Pulmatrix equity holders, warrants to certain Pulmatrix warrant holders, and conversion of Pulmatrix bridge loans into Ruthigen common stock.
Material Changes and Corporate Actions
On June 12, 2015, Ruthigen stockholders approved five key proposals required to consummate the merger with Pulmatrix:
- Merger Approval: Approved the Merger Agreement and related transactions.
- Equity Plan Amendment: Increased shares available for grant under the 2013 Equity Incentive Plan to 6,853,319 pre-reverse split shares and added performance-based awards.
- Reverse Stock Split: Approved a reverse stock split with a ratio between 1-for-2.5 and 1-for-4.
- Executive Employment: Approved employment agreements for CEO Hojabr Alimi and CFO Sameer Harish, including cash and restricted stock units.
- Board Structure: The proposal to declassify the board of directors was not approved; the board will remain classified.
Pulmatrix stockholders also provided sufficient written consents to approve the Merger.
Outlook, Risks, and Contingencies
The primary contingency for the transaction is the successful closing of the Merger, which is now expected to proceed following stockholder approvals. The private placement shares are exempt from registration under Section 4(a)(2) and Rule 506(b) of Regulation D. Investors are urged to review the definitive joint proxy and consent solicitation statement/prospectus filed on Form S-4 for comprehensive risk factors and transaction details.
Investor Verification Checklist
- Verify the final closing date of the Merger and the private placement.
- Confirm the exact reverse stock split ratio (between 1-for-2.5 and 1-for-4) once finalized.
- Review the definitive proxy statement for details on the conversion terms of Pulmatrix bridge loans.
- Check for any subsequent filings regarding the issuance of shares to Pulmatrix equity holders.